WebinarReplay:PersonalizedCancerTreatment

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

 Google Tag Manager snippet added by Site Kit 

 End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Advancing personalized cancer treatment: Webinar Replay 

Webinar replay available now: Unlocking precision medicine through expert NGS panel design 

Discover the Future of Personalized Cancer Treatment

Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research and treatment. If you missed the live session or wish to revisit the insightful presentations, we’re offering exclusive access to the replay.

This webinar featured leading experts in the field, discussing how our OncoDEEP® Kit and innovative technologies like Twist hybrid capture are transforming the landscape of cancer treatment through personalized medicine and precision diagnostics.

What you’ll learn:Revolutionary personalized treatments: Insights into OncoDEEP’s approach to cancer therapy and its potential to change patient care.Expert perspectives on genomic signatures: An exploration of complex genomic signatures, including HRD, TMB, MSI, and LOH, and their significance in cancer research.Innovative technology: The impact of Twist hybrid capture technology on cancer research and its role in improving test efficiency.Real-world impact: Case studies from leading German healthcare providers, showcasing the practical application and effectiveness of these innovations.Maximizing NGS data: Strategies for exploiting next-generation sequencing data to improve research outcomes and patient care. 

To view the replay, please enter your details below. 

Position / Job Title 

Assistant Professor & Head Molecular Diagnostics and Research — Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster 

Head of Scientific & KDO, OncoDNA 

Staff Product Manager, Twist Bioscience 

You may also be interested in these resources 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Press Release
OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, NetherlandsNov 7th

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...Read more →

 Press Release
OncoDNA wins the Biotech Award of Deloitte’s 2020 Technology Fast50 competitionNov 27th

Gosselies, 27 november 2020 – Already celebrated by Deloitte’s Technology Fast50 in 2015 and 2018, OncoDNA is thrilled to announce that it has received this year’s Award in the biotechnology and pharmaceutical category. Deloitte’s Technology...Read more →

 Scientific Application Note
LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectivelyMay 11th

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell...Read more → 

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

Support 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712129247